Return to work: key issues for life sciences
by Helen Farr and Adrian Toutoungi
Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
by multiple authors
4 of 6 Insights
Licensing out: Try not to get benched
by Colin McCall and Justyna Ostrowska
Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents
by multiple authors
IP: Licensing and insolvency
by multiple authors
UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
6 of 6 Insights
US buys up entire stock of remdesivir
Time to intervene?
Arbitration for life sciences companies
by multiple authors
